158 related articles for article (PubMed ID: 24713990)
1. Oncofetal protein IMP3, a new cancer biomarker.
Gong Y; Woda BA; Jiang Z
Adv Anat Pathol; 2014 May; 21(3):191-200. PubMed ID: 24713990
[TBL] [Abstract][Full Text] [Related]
2. Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma.
Cornejo K; Shi M; Jiang Z
Hum Pathol; 2012 Oct; 43(10):1567-72. PubMed ID: 22497850
[TBL] [Abstract][Full Text] [Related]
3. Oncofetal protein IMP3: a new diagnostic biomarker for laryngeal carcinoma.
Chen K; Cornejo KM; Ye W; Wu Q; Liang J; Jiang Z
Hum Pathol; 2013 Oct; 44(10):2126-31. PubMed ID: 23806529
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer.
Findeis-Hosey JJ; Xu H
Biotech Histochem; 2012 Jan; 87(1):24-9. PubMed ID: 21838610
[TBL] [Abstract][Full Text] [Related]
5. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma.
Yuan RH; Wang CC; Chou CC; Chang KJ; Lee PH; Jeng YM
Ann Surg Oncol; 2009 Jun; 16(6):1711-9. PubMed ID: 19357927
[TBL] [Abstract][Full Text] [Related]
6. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.
Szarvas T; Tschirdewahn S; Niedworok C; Kramer G; Sevcenco S; Reis H; Shariat SF; RĂ¼bben H; vom Dorp F
Int J Cancer; 2014 Oct; 135(7):1596-604. PubMed ID: 24615121
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value.
Wachter DL; Kristiansen G; Soll C; Hellerbrand C; Breuhahn K; Fritzsche F; Agaimy A; Hartmann A; Riener MO
Histopathology; 2012 Jan; 60(2):278-86. PubMed ID: 22211286
[TBL] [Abstract][Full Text] [Related]
9. The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma.
Hao S; Smith TW; Chu PG; Liu Q; Ok CY; Woda BA; Lu D; Lin P; Wang SA; Dresser K; Rock KL; Jiang Z
Arch Pathol Lab Med; 2011 Aug; 135(8):1032-6. PubMed ID: 21809995
[TBL] [Abstract][Full Text] [Related]
10. IMP3 Is Strongly Expressed in Malignant Phyllodes Tumors of the Breast: An Immunohistochemical Study.
Bellezza G; Prosperi E; Del Sordo R; Colella R; Rulli A; Sidoni A
Int J Surg Pathol; 2016 Feb; 24(1):37-42. PubMed ID: 26353850
[TBL] [Abstract][Full Text] [Related]
11. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
[TBL] [Abstract][Full Text] [Related]
12. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study.
Jiang Z; Chu PG; Woda BA; Rock KL; Liu Q; Hsieh CC; Li C; Chen W; Duan HO; McDougal S; Wu CL
Lancet Oncol; 2006 Jul; 7(7):556-64. PubMed ID: 16814207
[TBL] [Abstract][Full Text] [Related]
13. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia.
Lu D; Vohra P; Chu PG; Woda B; Rock KL; Jiang Z
Am J Surg Pathol; 2009 Apr; 33(4):521-5. PubMed ID: 19047899
[TBL] [Abstract][Full Text] [Related]
14. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.
Sitnikova L; Mendese G; Liu Q; Woda BA; Lu D; Dresser K; Mohanty S; Rock KL; Jiang Z
Clin Cancer Res; 2008 Mar; 14(6):1701-6. PubMed ID: 18347170
[TBL] [Abstract][Full Text] [Related]
15. IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG.
Samanta S; Sun H; Goel HL; Pursell B; Chang C; Khan A; Greiner DL; Cao S; Lim E; Shultz LD; Mercurio AM
Oncogene; 2016 Mar; 35(9):1111-21. PubMed ID: 25982283
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of IMP3 between male and female mature teratomas--immunohistochemical evidence of malignant nature.
Goodman S; Zhang L; Cheng L; Jiang Z
Histopathology; 2014 Oct; 65(4):483-9. PubMed ID: 24605891
[TBL] [Abstract][Full Text] [Related]
17. IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.
Yan J; Wei Q; Jian W; Qiu B; Wen J; Liu J; Fu B; Zhou X; Zhao T
Lung; 2016 Feb; 194(1):137-46. PubMed ID: 26608347
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer.
Hsu KF; Shen MR; Huang YF; Cheng YM; Lin SH; Chow NH; Cheng SW; Chou CY; Ho CL
Br J Cancer; 2015 Jul; 113(3):414-24. PubMed ID: 26158423
[TBL] [Abstract][Full Text] [Related]
19. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.
Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S
Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
Kanzaki A; Kudo M; Ansai S; Peng WX; Ishino K; Yamamoto T; Wada R; Fujii T; Teduka K; Kawahara K; Kawamoto Y; Kitamura T; Kawana S; Saeki H; Naito Z
Int J Oncol; 2016 Mar; 48(3):1007-15. PubMed ID: 26782292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]